Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells

Chemoresistance mechanisms of colorectal cancer remain largely elusive. We aim to compare the difference of chemotherapy responses between FOLFOX-resistant and wild-type colorectal cancer cells by proteomic profiling to suggest novel treatment targets. FOLFOX-resistant colorectal cancer cells DLD1-R...

Full description

Bibliographic Details
Main Authors:	Shing-Yau Tam, Md Zahirul Islam Khan, Ju-Yu Chen, Jerica Hiu-Yui Yip, Hong-Yiu Yan, Tsz-Yan Tam, Helen Ka-Wai Law
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	International Journal of Molecular Sciences
Subjects:	chemoresistance colorectal cancer cytoskeleton FOLFOX proteomic profiling ribosome
Online Access:	https://www.mdpi.com/1422-0067/24/12/9899

Similar Items

Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats
by: Juste Maneikyte, et al.
Published: (2020-08-01)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
by: Ren Hui, et al.
Published: (2011-09-01)

Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
by: Lyu Ning, et al.
Published: (2022-01-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma
by: Domenico D’Arca, et al.
Published: (2023-01-01)

High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data
by: Soukaina Amniouel, et al.
Published: (2024-01-01)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
by: Shyam Aggarwal
Published: (2015-11-01)

Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
by: Liu X, et al.
Published: (2021-01-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment
by: Zhou Y, et al.
Published: (2023-06-01)

Advances in High Throughput Proteomics Profiling in Establishing Potential Biomarkers for Gastrointestinal Cancer
by: Md Zahirul Islam Khan, et al.
Published: (2022-03-01)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
by: Xiaoying Hou, et al.
Published: (2021-09-01)

Drug-Induced Interstitial Pneumonia due to Application of FOLFOX as Adjuvant Chemotherapy after Rectal Cancer Surgery: A Case Report and Literature Review
by: Senichiro Yanagawa, et al.
Published: (2020-07-01)

miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
by: Kha Wai Hon, et al.
Published: (2018-08-01)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
by: Vincenza Conteduca, et al.
Published: (2018-12-01)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
by: Erin D. Powell, et al.
Published: (2009-07-01)

Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3Research in context
by: Guifang Li, et al.
Published: (2024-04-01)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
by: Jii Bum Lee, et al.
Published: (2020-04-01)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
by: Kohei Shitara, et al.
Published: (2010-07-01)

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy
by: Tao Y, et al.
Published: (2019-04-01)

Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study
by: Min-Ke He, et al.
Published: (2017-10-01)

The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis
by: Yurika Nakayama, et al.
Published: (2024-01-01)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
by: Yiyi Zhang, et al.
Published: (2021-01-01)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

Global impact of KRAS mutations patterns in FOLFOX treated metastatic colorectal cancer
by: David eMolinas Zocche, et al.
Published: (2015-03-01)

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
by: Satoshi Kobayashi, et al.
Published: (2023-02-01)

Analysis of capecitabine plus oxaliplatin (xelox) combination in the management of metastatic colorectal cancer compare with fluorouracil and oxaliplatin combination (folfox)
by: Isnatin Miladiyah
Published: (2016-12-01)

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
by: Mehdi Dehghani, et al.
Published: (2015-07-01)

Protective effect of miR‐18a in resected liver metastases of colorectal cancer and FOLFOX treatment
by: Clemens Franz, et al.
Published: (2023-12-01)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
by: Wei Lu, et al.
Published: (2020-02-01)

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
by: Shukui Qin, et al.
Published: (2018-08-01)

Retrospective Analysis of the Safety of FOLFOX Compared to CAPOX for Adjuvant Treatment of Stage III Colorectal Cancer in Newfoundland Patients
by: Joshua N. McShane, et al.
Published: (2022-09-01)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
by: Taku Naiki, et al.
Published: (2017-11-01)

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report
by: Clizia Zichi, et al.
Published: (2018-04-01)

A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Preoperative FOLFOX Chemotherapy Followed by Radical Subtotal Gastrectomy and D2 Lymph Node Dissection
by: Byoung Jo Suh
Published: (2017-02-01)

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
by: Meiling Yang, et al.
Published: (2023-07-01)

LABS score– a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study
by: Jirapat Wonglhow, et al.
Published: (2024-03-01)

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia
by: Dhouha Jamai, et al.
Published: (2023-07-01)

FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis
by: Yiyi Zhang, et al.
Published: (2020-03-01)